This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
TolerRx brings in $35.6mm with its latest venture round
21 Sep 2006
TolerRx (immune system therapeutics) has raised $35.6mm with its latest venture round. New investor FrontPoint Partners led the round and was joined by other new backers Mesirow Financial, Swiss Re, QVT Fund, IBT Management, Brookstone Capital, and the Juvenile Diabetes Research Foundation. Returning participants included Skyline Ventures, Bear Stearns, Sprout Group, Rho Ventures, Artal Services, and HealthCare Ventures. TolerRx will use the funds to continue developing the anti-CD3 monoclonal antibody TRX4, its lead candidate that is in Phase II for Type I diabetes and Phase I for psoriasis.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?